Ashok Kumar Windlass steps down as whole-time director under succession plan

Key managerial personnel resignedManagement Changes View source PDF Explain this filing

WINDLAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+8.7%Reaction day

₹918.00

prior close

₹914.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.3%+9.0% vs sector

On the reaction day the stock moved 9.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+6.6

10m

+6.9

15m

+10.4

30m

+10.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+8.7pendingpending-0.3+9.0

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ashok Kumar Windlass resigned as whole-time director and board member effective November 5, 2026, citing succession planning. He will serve as Founder President from November 6, subject to shareholder approval, at Rs 1.56 crore a year. Hitesh Windlass, the managing director, was appointed chairman. September-quarter revenue rose 18.7% to Rs 263.91 crore, while profit rose 1.4% to Rs 18.05 crore; first-half revenue rose 18.4% and profit 0.7%.

Likely market impact

Succession looks orderly, but the founder stays in a senior role and his son gains board leadership. Strong sales with flat profit may limit upside.